BioLineRx Ltd (BLRX) - Financial and Strategic SWOT Analysis Review

November 2021 | 53 pages | ID: B49BB04EFAAEN
GlobalData

Abstracts

BioLineRx Ltd (BLRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is a short peptide that is in Phase IIb clinical trial studies for acute myeloid leukemia (AML), Phase III studies for autologous transplantation and completed Phase IIa clinical trials for relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx’s only product BL-5010 is a novel medical device indicated for non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in, Israel.

BioLineRx Ltd Key Recent Developments

Aug 18,2021: BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
May 26,2021: BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
Feb 23,2021: BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update
Feb 17,2021: BioLineRx to Report Annual 2020 Results on February 23, 2021
Nov 23,2020: BioLineRx biolinerx reports third quarter 2020 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

BioLineRx Ltd - Key Facts
BioLineRx Ltd - Key Employees
BioLineRx Ltd - Key Employee Biographies
BioLineRx Ltd - Major Products and Services
BioLineRx Ltd - History
BioLineRx Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
BioLineRx Ltd - Business Description
BioLineRx Ltd - Corporate Strategy
BioLineRx Ltd - SWOT Analysis
SWOT Analysis - Overview
BioLineRx Ltd - Strengths
BioLineRx Ltd - Weaknesses
BioLineRx Ltd - Opportunities
BioLineRx Ltd - Threats
BioLineRx Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioLineRx Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 18, 2021: BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
May 26, 2021: BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
Feb 23, 2021: BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update
Feb 17, 2021: BioLineRx to Report Annual 2020 Results on February 23, 2021
Nov 23, 2020: BioLineRx biolinerx reports third quarter 2020 financial results and provides corporate update
Aug 06, 2020: BioLineRx reports second quarter 2020 financial results and provides corporate update
May 20, 2020: BioLineRx reports first quarter 2020 financial results and provides corporate update
May 15, 2020: BioLineRx to Report First Quarter 2020 Results on May 20, 2020
Mar 12, 2020: BioLineRx reports year-end 2019 financial results and provides corporate update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

BioLineRx Ltd, Key Facts
BioLineRx Ltd, Key Employees
BioLineRx Ltd, Key Employee Biographies
BioLineRx Ltd, Major Products and Services
BioLineRx Ltd, History
BioLineRx Ltd, Subsidiaries
BioLineRx Ltd, Key Competitors
BioLineRx Ltd, Ratios based on current share price
BioLineRx Ltd, Annual Ratios
BioLineRx Ltd, Annual Ratios (Cont...1)
BioLineRx Ltd, Interim Ratios
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioLineRx Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

BioLineRx Ltd, Performance Chart (2016 - 2020)
BioLineRx Ltd, Ratio Charts
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021